Quoin Pharmaceuticals
Update in progressQNRX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Quoin Pharmaceuticals, Ltd. is a late-stage specialty pharma company focused on developing and commercializing therapies for rare and orphan diseases in the United States. Its lead product, QRX003, is a topical lotion in Phase 2 for netherton syndrome, Phase 1 for peeling skin syndrome, and preclinical for SAM syndrome and ichthyosis. QRX008 is preclinical for scleroderma, and QRX009 targets microcystic lymphatic and venous malformations and related conditions. The company has a research agreement with Queensland University of Technology. Founded in 2018 and based in Ashburn, Virginia, Quoin is a subsidiary of Skinvisible, Inc.
Company score
- Sentiment
- 0.40
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.26
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.25
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Michael Myers Ph.D.
- Founded2018
- Employees4
- Websitequoinpharma.com
Identifiers
- ISINUS74907L1026
- FIGIBBG00D9PB2L6
- CUSIP74907L102
- CIK0001671502